Literature DB >> 26378276

The Race Is On To Shorten the Turnaround Time for Diagnosis of Multidrug-Resistant Tuberculosis.

Akos Somoskovi1, Max Salfinger2.   

Abstract

To realize the most benefit from multidrug-resistant tuberculosis (MDR-TB) screening, all nucleic acid amplification test (NAAT)-positive respiratory specimens should be universally tested. Once an MDR-TB diagnosis is established, additional testing is warranted to provide details about the detected mutations. The lab-on-chip technology described by A. M. Cabibbe et al. (J Clin Microbiol 53:3876-3880, 2015, http://dx.doi.org/10.1128/JCM.01824-15) potentially provides this much needed information.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Year:  2015        PMID： 26378276      PMCID： PMC4652131          DOI： 10.1128/JCM.02398-15

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  27 in total

1.  Molecular characterization of rifampin-resistant isolates of Mycobacterium tuberculosis from Hungary by DNA sequencing and the line probe assay.

Authors:  Z Bártfai; A Somoskövi; C Ködmön; N Szabó; E Puskás; L Kosztolányi; E Faragó; J Mester; L M Parsons; M Salfinger
Journal:  J Clin Microbiol       Date:  2001-10       Impact factor: 5.948

Review 2.  The ins and outs of Mycobacterium tuberculosis drug susceptibility testing.

Authors:  E C Böttger
Journal:  Clin Microbiol Infect       Date:  2011-06-01       Impact factor: 8.067

3.  Molecular analysis of cross-resistance to capreomycin, kanamycin, amikacin, and viomycin in Mycobacterium tuberculosis.

Authors:  Courtney E Maus; Bonnie B Plikaytis; Thomas M Shinnick
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

4.  Use of smear-positive samples to assess the PCR-based genotype MTBDR assay for rapid, direct detection of the Mycobacterium tuberculosis complex as well as its resistance to isoniazid and rifampin.

Authors:  Akos Somoskovi; Jillian Dormandy; Dimitra Mitsani; Jeremy Rivenburg; Max Salfinger
Journal:  J Clin Microbiol       Date:  2006-10-11       Impact factor: 5.948

5.  Rise in rifampicin-monoresistant tuberculosis in Western Cape, South Africa.

Authors:  F K Mukinda; D Theron; G D van der Spuy; K R Jacobson; M Roscher; E M Streicher; A Musekiwa; G J Coetzee; T C Victor; B J Marais; J B Nachega; R M Warren; H S Schaaf
Journal:  Int J Tuberc Lung Dis       Date:  2012-02       Impact factor: 2.373

6.  New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variability.

Authors:  Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2010-01-19       Impact factor: 5.191

7.  Rapid colorimetric testing for pyrazinamide susceptibility of M. tuberculosis by a PCR-based in-vitro synthesized pyrazinamidase method.

Authors:  Man Zhou; Xuelei Geng; Jun Chen; Xude Wang; Dianbing Wang; Jiaoyu Deng; Zhiping Zhang; Weihua Wang; Xian-En Zhang; Hongping Wei
Journal:  PLoS One       Date:  2011-11-10       Impact factor: 3.240

8.  Need to confirm isoniazid susceptibility in Xpert MTB/RIF rifampin susceptible cases.

Authors:  Viral Vadwai; Catharina Boehme; Pamela Nabeta; Anjali Shetty; Camilla Rodrigues
Journal:  Indian J Med Res       Date:  2012-04       Impact factor: 2.375

Review 9.  The molecular basis of resistance to isoniazid, rifampin, and pyrazinamide in Mycobacterium tuberculosis.

Authors:  A Somoskovi; L M Parsons; M Salfinger
Journal:  Respir Res       Date:  2001-04-05

10.  Quantitative drug-susceptibility in patients treated for multidrug-resistant tuberculosis in Bangladesh: implications for regimen choice.

Authors:  Scott K Heysell; Shahriar Ahmed; Sara Sabrina Ferdous; Md Siddiqur Rahman Khan; S M Mazidur Rahman; Jean Gratz; Md Toufiq Rahman; Asif Mujtaba Mahmud; Eric R Houpt; Sayera Banu
Journal:  PLoS One       Date:  2015-02-24       Impact factor: 3.240
View more
  4 in total

1.  Role of Disputed Mutations in the rpoB Gene in Interpretation of Automated Liquid MGIT Culture Results for Rifampin Susceptibility Testing of Mycobacterium tuberculosis.

Authors:  Paolo Miotto; Andrea M Cabibbe; Emanuele Borroni; Massimo Degano; Daniela M Cirillo
Journal:  J Clin Microbiol       Date:  2018-04-25       Impact factor: 5.948

2.  Sequence Analysis of Fluoroquinolone Resistance-Associated Genes gyrA and gyrB in Clinical Mycobacterium tuberculosis Isolates from Patients Suspected of Having Multidrug-Resistant Tuberculosis in New Delhi, India.

Authors:  Ritu Singhal; Paul R Reynolds; Jamie L Marola; L Elaine Epperson; Jyoti Arora; Rohit Sarin; Vithal Prasad Myneedu; Michael Strong; Max Salfinger
Journal:  J Clin Microbiol       Date:  2016-06-22       Impact factor: 5.948

Review 3.  Practice Guidelines for Clinical Microbiology Laboratories: Mycobacteria.

Authors:  Betty A Forbes; Geraldine S Hall; Melissa B Miller; Susan M Novak; Marie-Claire Rowlinson; Max Salfinger; Akos Somoskövi; David M Warshauer; Michael L Wilson
Journal:  Clin Microbiol Rev       Date:  2018-01-31       Impact factor: 26.132

4.  A pilot study: VereMTB detection kit for rapid detection of multidrug-resistant mycobcterium tuberculosis in clinical sputum samples.

Authors:  Xichao Ou; Qiang Li; Dan Su; Hui Xia; Shengfen Wang; Bing Zhao; Yanlin Zhao
Journal:  PLoS One       Date:  2020-03-09       Impact factor: 3.240
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.